Study Closeout Section
ICH E6(R3) explicitly includes site close-out in investigator-site monitoring and calls for confirmation of essential-record retention and final investigational-product accountability. A closeout description should focus on operational completion rather than a manuscript conclusion.
A Study Closeout section describes how trial sites and responsibilities will be formally closed, including final records, unresolved actions, and investigational-product accountability where applicable.
Key details
Important caveats
Scope Boundary
Closeout procedures vary with sponsor, intervention, site model, regulation, and risk. Do not present a single checklist as universal or confuse site closeout with participant follow-up or publication.
Further guidance
Content
Describe final reconciliation or follow-up tasks, essential-record retention arrangements, outstanding reporting, access responsibilities, and final product accountability when applicable.
Purpose
Define what must be completed and verified before a site or study is considered operationally closed.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification